Literature DB >> 31892563

Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells.

Edgar Heinz Uwe Wendt1, Maria Schoenrogge1, Brigitte Vollmar1, Dietmar Zechner2.   

Abstract

BACKGROUND/AIM: In this study, we evaluated the effect of galloflavin, an inhibitor of lactate dehydrogenase, in combination with metformin, an anti-diabetic drug and inhibitor of oxidative phosphorylation, on pancreatic ductal adenocarcinoma cells.
MATERIALS AND METHODS: We explored the effect of galloflavin and metformin on proliferation and cell death of murine 6606PDA and human MIA PaCa-2 cells.
RESULTS: We observed that monotherapies of galloflavin and metformin both inhibit proliferation and induce cancer cell death. Moreover, the combination of both agents increased these effects on pancreatic ductal adenocarcinoma cells. The inhibition of proliferation by this combination therapy can be detected under hypoxic and normoxic conditions, leading to the assumption that this therapy might impair insufficiently supplied solid tumors as well as small clusters of cancer cells, e.g. after metastatic dissemination.
CONCLUSION: Galloflavin, especially in combination with metformin, has a strong anti-cancerous effect on pancreatic ductal adenocarcinoma cells. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Pancreatic ductal adenocarcinoma; anti-diabetic medication; cancer metabolism; combination therapy; polytherapy

Mesh:

Substances:

Year:  2020        PMID: 31892563     DOI: 10.21873/anticanres.13936

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Targeting Energy Metabolism in Cancer Treatment.

Authors:  Joanna Kubik; Ewelina Humeniuk; Grzegorz Adamczuk; Barbara Madej-Czerwonka; Agnieszka Korga-Plewko
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway.

Authors:  Yao Lu; Dao Xin; Lulu Guan; Mengli Xu; Yalan Yang; Yu Chen; Yuanyuan Yang; Andrea Wang-Gillam; Li Wang; Shanggang Zong; Feng Wang
Journal:  Front Oncol       Date:  2021-11-22       Impact factor: 6.244

3.  Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism.

Authors:  Simone Kumstel; Tim Schreiber; Lea Goldstein; Jan Stenzel; Tobias Lindner; Markus Joksch; Xianbin Zhang; Edgar Heinz Uwe Wendt; Maria Schönrogge; Bernd Krause; Brigitte Vollmar; Dietmar Zechner
Journal:  PLoS One       Date:  2022-04-22       Impact factor: 3.240

4.  Galloflavin Relieves the Malignant Behavior of Colorectal Cancer Cells in the Inflammatory Tumor Microenvironment.

Authors:  Li Guo; Yi Yang; Yongjia Sheng; Jin Wang; Wenyan Li; Xiaohong Zhou; Shuiliang Ruan; Chenyang Han
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.